

William Hasler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5343001/publications.pdf>

Version: 2024-02-01

161
papers

11,271
citations

41258

49
h-index

30010

103
g-index

166
all docs

166
docs citations

166
times ranked

5314
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastroduodenal Disorders. <i>Gastroenterology</i> , 2016, 150, 1380-1392.	0.6	1,088
2	American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. <i>Gastroenterology</i> , 2004, 127, 1592-1622.	0.6	644
3	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. <i>American Journal of Gastroenterology</i> , 2008, 103, 753-763.	0.2	588
4	Effect of Octreotide on Intestinal Motility and Bacterial Overgrowth in Scleroderma. <i>New England Journal of Medicine</i> , 1991, 325, 1461-1467.	13.9	383
5	Cellular Changes in Diabetic and Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2011, 140, 1575-1585.e8.	0.6	368
6	Measurement of gastrointestinal motility in the GI laboratory. <i>Gastroenterology</i> , 1998, 115, 747-762.	0.6	317
7	Treatment of gastroparesis: a multidisciplinary clinical review. The American Motility Society Task Force on Gastroparesis (members in alphabetical order). <i>Neurogastroenterology and Motility</i> , 2006, 18, 263-283.	1.6	316
8	Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. <i>Neurogastroenterology and Motility</i> , 2011, 23, 8-23.	1.6	305
9	Investigation of Colonic and Whole-Gut Transit With Wireless Motility Capsule and Radiopaque Markers in Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 537-544.	2.4	297
10	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. <i>Journal of Nuclear Medicine Technology</i> , 2008, 36, 44-54.	0.4	295
11	Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 186-196.	1.9	293
12	Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. <i>Neurogastroenterology and Motility</i> , 2003, 15, 89-102.	1.6	286
13	Clinical Features of Idiopathic Gastroparesis Vary With Sex, Body Mass, Symptom Onset, Delay in Gastric Emptying, and Gastroparesis Severity. <i>Gastroenterology</i> , 2011, 140, 101-115.e10.	0.6	281
14	Characteristics of Patients With Chronic Unexplained Nausea and Vomiting and Normal Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 567-576.e4.	2.4	212
15	Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. <i>Gastroenterology</i> , 1995, 108, 727-736.	0.6	210
16	American Gastroenterological Association medical position statement: Diagnosis and treatment of gastroparesis. <i>Gastroenterology</i> , 2004, 127, 1589-1591.	0.6	191
17	Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. <i>Neurogastroenterology and Motility</i> , 2010, 22, 874.	1.6	185
18	Similarities and Differences Between Diabetic and Idiopathic Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 1056-1064.	2.4	174

#	ARTICLE	IF	CITATIONS
19	Cyclic vomiting syndrome in adults. <i>Neurogastroenterology and Motility</i> , 2008, 20, 269-284.	1.6	172
20	Clinical–histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. <i>Neurogastroenterology and Motility</i> , 2012, 24, 531.	1.6	164
21	Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2640.	3.8	149
22	Dietary Intake and Nutritional Deficiencies in Patients With Diabetic or Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2011, 141, 486-498.e7.	0.6	148
23	The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 313-322.	1.9	123
24	Regional gastrointestinal transit and <scp>pH</scp> studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocol. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 761-772.	1.9	117
25	Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. <i>Gastroenterology</i> , 2018, 154, 65-76.e11.	0.6	117
26	Factors Associated with Symptom Response to Pyloric Injection of Botulinum Toxin in a Large Series of Gastroparesis Patients. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2634-2642.	1.1	114
27	Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis. <i>Gastroenterology</i> , 2015, 149, 1762-1774.e4.	0.6	110
28	Ultrastructural differences between diabetic and idiopathic gastroparesis. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1573-1581.	1.6	104
29	Psychological Dysfunction Is Associated With Symptom Severity but Not Disease Etiology or Degree of Gastric Retention in Patients With Gastroparesis. <i>American Journal of Gastroenterology</i> , 2010, 105, 2357-2367.	0.2	103
30	Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. <i>Neurogastroenterology and Motility</i> , 2013, 25, 427.	1.6	103
31	Gastroparesis: Symptoms, Evaluation, and Treatment. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 619-647.	1.0	100
32	Gastroparesis: pathogenesis, diagnosis and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 438-453.	8.2	95
33	The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation. <i>Nature Microbiology</i> , 2017, 2, 16267.	5.9	94
34	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for <i>in Vivo</i> Dissolution and Absorption of Ionizable Drugs. <i>Molecular Pharmaceutics</i> , 2017, 14, 4281-4294.	2.3	94
35	Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. <i>Neurogastroenterology and Motility</i> , 2010, 22, 527-33, e117.	1.6	91
36	Methods of gastric electrical stimulation and pacing: a review of their benefits and mechanisms of action in gastroparesis and obesity. <i>Neurogastroenterology and Motility</i> , 2009, 21, 229-243.	1.6	87

#	ARTICLE	IF	CITATIONS
37	Association of low numbers of ^{CD}206 ⁺ positive cells with loss of ^{ICC} in the gastric body of patients with diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1275-1284.	1.6	83
38	Generalized Transit Delay on Wireless Motility Capsule Testing in Patients with Clinical Suspicion of Gastroparesis, Small Intestinal Dysmotility, or Slow Transit Constipation. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2928-2938.	1.1	76
39	Abdominal and pelvic surgery in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 997-1005.	1.9	70
40	Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G1107-G1114.	1.6	70
41	Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13606.	1.6	70
42	Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13196.	1.6	65
43	Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1902-1914.	1.6	61
44	Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1285-1294.e1.	2.4	60
45	Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy (with video). <i>Gastrointestinal Endoscopy</i> , 2020, 91, 1289-1299.	0.5	59
46	Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12981.	1.6	57
47	Nausea and vomiting. <i>Gastroenterology</i> , 2003, 125, 1860-1867.	0.6	56
48	Spatial and Temporal Analysis of the Stomach and Small-Intestinal Microbiota in Fasted Healthy Humans. <i>MSphere</i> , 2019, 4, .	1.3	55
49	Coupling and propagation of normal and dysrhythmic gastric slow waves during acute hyperglycaemia in healthy humans. <i>Neurogastroenterology and Motility</i> , 2009, 21, 492.	1.6	54
50	Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1770-1779.e2.	2.4	53
51	Bloating in Gastroparesis: Severity, Impact, and Associated Factors. <i>American Journal of Gastroenterology</i> , 2011, 106, 1492-1502.	0.2	52
52	Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1001-1015.	1.6	51
53	Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. <i>Journal of Nuclear Medicine</i> , 2018, 59, 691-697.	2.8	48
54	Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1994, 268, 1206-11.	1.3	48

#	ARTICLE	IF	CITATIONS
55	Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT ₃ pathways. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, G400-G407.	1.6	46
56	<i>In Vivo</i> Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. <i>Molecular Pharmaceutics</i> , 2017, 14, 4295-4304.	2.3	46
57	Ethnic, Racial, and Sex Differences in Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1489-1499.e8.	2.4	43
58	Serotonin and the GI tract. <i>Current Gastroenterology Reports</i> , 2009, 11, 383-391.	1.1	42
59	Traditional Thoughts on the Pathophysiology of Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 21-43.	1.0	42
60	Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2242-2255.	1.1	42
61	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded "21st Century BA/BE"™ project. <i>International Journal of Pharmaceutics</i> , 2018, 548, 120-127.	2.6	41
62	Measurement of <i>in vivo</i> Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. <i>Molecular Pharmaceutics</i> , 2017, 14, 345-358.	2.3	39
63	Differential symptomatic and electrogastrographic effects of distal and proximal human gastric distension. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, G418-G424.	1.6	38
64	Differential 5-HT ₃ mediation of human gastrocolonic response and colonic peristaltic reflex. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, G498-G505.	1.6	37
65	Gastroparesis. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 621-628.	1.0	37
66	Regional gastrointestinal contractility parameters using the wireless motility capsule: interobserver reproducibility and influence of age, gender and study country. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 391-400.	1.9	37
67	Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: Relationship with etiology, gastric emptying, and symptom severity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13810.	1.6	37
68	Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, G1384-G1391.	1.6	36
69	Effectiveness of gastric electrical stimulation in gastroparesis: Results from a large prospectively collected database of national gastroparesis registries. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13714.	1.6	36
70	Gastroparesis—current concepts and considerations. <i>Medscape Journal of Medicine</i> , 2008, 10, 16.	0.6	36
71	The use of SmartPill for gastric monitoring. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 587-600.	1.4	35
72	Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13607.	1.6	35

#	ARTICLE	IF	CITATIONS
73	Delayed Gastric Emptying Associates With Diabetic Complications in Diabetic Patients With Symptoms of Gastroparesis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1778-1794.	0.2	34
74	Endoscopic Gastric Food Retention in Relation to Scintigraphic Gastric Emptying Delays and Clinical Factors. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2593-2601.	1.1	33
75	Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. <i>PLoS ONE</i> , 2018, 13, e0194759.	1.1	33
76	Pharmacotherapy for intestinal motor and sensory disorders. <i>Gastroenterology Clinics of North America</i> , 2003, 32, 707-732.	1.0	31
77	Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1996, 277, 1359-65.	1.3	29
78	The irritable bowel syndrome during pregnancy. <i>Gastroenterology Clinics of North America</i> , 2003, 32, 385-406.	1.0	27
79	A technical review and clinical assessment of the wireless motility capsule. <i>Gastroenterology and Hepatology</i> , 2011, 7, 795-804.	0.2	27
80	Dumping syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2002, 5, 139-145.	0.3	26
81	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 129, 162-174.	2.0	24
82	Cholecystectomy and Clinical Presentations of Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1062-1073.	1.1	23
83	Constipation in Patients With Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 546-558.e5.	2.4	23
84	Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14339.	1.6	23
85	Opioids and GI Motility—Friend or Foe?. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 478-494.	0.3	22
86	Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. <i>AAPS Journal</i> , 2017, 19, 1682-1690.	2.2	22
87	Impact of gastric peroral endoscopic myotomy on static and dynamic pyloric function in gastroparesis patients. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13892.	1.6	22
88	Blunting of Colon Contractions in Diabetics with Gastroparesis Quantified by Wireless Motility Capsule Methods. <i>PLoS ONE</i> , 2015, 10, e0141183.	1.1	21
89	Central cholinergic and alpha-adrenergic mediation of gastric slow wave dysrhythmias evoked during motion sickness. <i>American Journal of Physiology - Renal Physiology</i> , 1995, 268, G539-G547.	1.6	19
90	Small Intestinal Bacterial Overgrowth: Clinical Presentation in Patients with Roux-en-Y Gastric Bypass. <i>Obesity Surgery</i> , 2021, 31, 564-569.	1.1	19

#	ARTICLE	IF	CITATIONS
91	Pathology of emesis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 337-352.	1.0	18
92	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	1.9	18
93	Erythromycin contracts rabbit colon myocytes via occupation of motilin receptors. American Journal of Physiology - Renal Physiology, 1992, 262, G50-G55.	1.6	17
94	Safety Profile of Tegaserod, a 5-HT4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome. Drug Safety, 2004, 27, 619-631.	1.4	17
95	Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. PLoS ONE, 2017, 12, e0187772.	1.1	17
96	Serotonin receptor physiology: relation to emesis. Digestive Diseases and Sciences, 1999, 44, 108S-113S.	1.1	16
97	Can High-Resolution Anorectal Manometry Shed New Light on Defecatory Disorders?. Gastroenterology, 2013, 144, 263-265.	0.6	15
98	Methodologic considerations for studies of chronic nausea and vomiting in adults and children. Autonomic Neuroscience: Basic and Clinical, 2017, 202, 28-39.	1.4	15
99	Management of cyclic vomiting syndrome in adults: Evidence review. Neurogastroenterology and Motility, 2019, 31, e13605.	1.6	15
100	Modulation of Intestinal Gas Dynamics in Healthy Human Volunteers by the 5-HT4 Receptor Agonist Tegaserod. American Journal of Gastroenterology, 2006, 101, 1858-1865.	0.2	14
101	The Physiology of Gastric Motility and Gastric Emptying. , 0, , 207-230.		14
102	Symptomatic Management for Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, 113-126.	1.0	14
103	Regional cholinergic differences between distal and proximal colonic myenteric plexus. American Journal of Physiology - Renal Physiology, 1990, 258, G404-G410.	1.6	13
104	Nutrient modulation of intestinal gas dynamics in healthy humans: dependence on caloric content and meal consistency. American Journal of Physiology - Renal Physiology, 2006, 291, G389-G395.	1.6	13
105	Influence of Gastric Emptying and Gut Transit Testing on Clinical Management Decisions in Suspected Gastroparesis. Clinical and Translational Gastroenterology, 2019, 10, e00084.	1.3	13
106	Nausea, Gastroparesis, and Aerophagia. Journal of Clinical Gastroenterology, 2005, 39, S223-S229.	1.1	12
107	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	2.3	12
108	Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity. Neurogastroenterology and Motility, 2020, 32, e13720.	1.6	12

#	ARTICLE	IF	CITATIONS
109	The irritable bowel syndrome. <i>Medical Clinics of North America</i> , 2002, 86, 1525-1551.	1.1	11
110	Aprepitant for Symptoms of Gastroparesis and Related Disorders: The APRON Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2016, 111, S480-S481.	0.2	11
111	Newest Drugs for Chronic Unexplained Nausea and Vomiting. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 371-385.	0.3	11
112	Irritable bowel syndrome and bloating. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 689-707.	1.0	10
113	Emerging drugs for the treatment of gastroparesis. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 261-279.	1.0	10
114	1069 Changes in Quality of Life and Symptoms in a Large Cohort of Patients With Gastroparesis Followed Prospectively for 48 Weeks. <i>Gastroenterology</i> , 2010, 138, S-155.	0.6	9
115	Diabetes and the Stomach. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 441-459.	0.3	9
116	Type 1 diabetes and gastroparesis: Diagnosis and treatment. <i>Current Gastroenterology Reports</i> , 2007, 9, 261-269.	1.1	8
117	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. <i>PLoS ONE</i> , 2020, 15, e0241441.	1.1	8
118	Bradykinin acting on B2 receptors contracts colon circular muscle cells by IP3 generation and adenylate cyclase inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995, 273, 344-50.	1.3	8
119	Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with Diabetes and Symptoms of Gastroparesis. <i>Frontiers in Endocrinology</i> , 2018, 9, 32.	1.5	7
120	G-POEM for Gastroparesis: Is There Pressure to Go with the Flow?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2165-2167.	1.1	7
121	Management of gastroparesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 411-423.	1.4	6
122	GI Motility Testing. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 159-169.	1.1	6
123	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. <i>AAPS Journal</i> , 2020, 22, 3.	2.2	6
124	Effects of nutrients and serotonin 5-HT3 antagonism on symptoms evoked by distal gastric distension in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G201-G208.	1.6	5
125	296 Effectiveness of Gastric Electrical Stimulation in Gastroparesis: Results From a Large Prospectively Collected Database of a National Gastroparesis Registry. <i>Gastroenterology</i> , 2015, 148, S-65.	0.6	5
126	Propagation Characteristics of Fasting Duodeno-Jejunal Contractions in Healthy Controls Measured by Clustered Closely-spaced Manometric Sensors. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 100-112.	0.8	5

#	ARTICLE	IF	CITATIONS
127	Baseline Predictors of Longitudinal Changes in Symptom Severity and Quality of Life in Patients With Suspected Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e407-e428.	2.4	5
128	M2023 Importance of Abdominal Pain as a Symptom in Gastroparesis: Relation to Clinical Factors, Disease Severity, Quality of Life, Gastric Retention, and Medication use. <i>Gastroenterology</i> , 2010, 138, S-461.	0.6	4
129	5 Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG).. <i>Gastroenterology</i> , 2013, 144, S-1.	0.6	4
130	295 Pilot Study of the Safety, Feasibility, and Efficacy of Continuous Glucose Monitoring (CGM) and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG): A Multicenter, Longitudinal Trial by the NIDDK Gastroparesis Clinical Research Consortium (GPCRC). <i>Gastroenterology</i> , 2015, 148, S-64.	0.6	4
131	Su1428 Wireless Motility Capsule Gastric and Extragastric Transit and Pressure Characteristics in a Large Patient Cohort With Gastroparesis Symptoms: Relation to Scintigraphic Findings and Disease Etiology. <i>Gastroenterology</i> , 2015, 148, S-507-S-508.	0.6	4
132	Cisapride acts on muscarinic (glandular M2) receptors to induce contraction of isolated gastric myocytes: mediation via a calcium-phosphoinositide pathway. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1991, 259, 1294-300.	1.3	4
133	Mo1285 Correlations of Liquid Nutrient Meal-Induced Symptoms With Satiety Test Volumes in Idiopathic Gastroparesis: Relation to Gastric Emptying and Myoelectric Activity. <i>Gastroenterology</i> , 2014, 146, S-608.	0.6	3
134	Su1449 Incidence and Clinical Significance of Delayed Gastric Emptying for Liquids in Gastroparesis and Chronic Unexplained Nausea and Vomiting (CUNV). <i>Gastroenterology</i> , 2015, 148, S-515.	0.6	3
135	Mo1599 Relation of Gastroparesis Symptom Severity to Gastric, Small Bowel, and Colon Transit and Contraction Profiles on Wireless Motility Capsule Testing in a Large Multicenter Cohort. <i>Gastroenterology</i> , 2016, 150, S725.	0.6	3
136	Geography Lessons: Scrutinizing State-by-State Differences in Inpatient Gastroparesis Care. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2743-2745.	1.1	2
137	Mo1292 Correlation of Fermentable Carbohydrate Consumption With Symptoms and Quality of Life in Patients With Diabetic and Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2014, 146, S-610.	0.6	2
138	Amitriptyline for Functional Dyspepsia: Importance of Symptom Profile and Making a Case for Gastric Emptying Testing. <i>Gastroenterology</i> , 2015, 149, 270-272.	0.6	2
139	Targeting Treatment of Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 519-538.	1.0	2
140	Diabetic Gastroparesis: Comparison of Clinical Features in Patients with Type 2 (T2DM) and Type 1 (T1DM) Diabetes Mellitus. <i>American Journal of Gastroenterology</i> , 2009, 104, S56.	0.2	2
141	S1333 A Comparison of Two Radio-Opaque Marker Methodologies in the Assessment of Colonic Transit of Adults With Constipation. <i>Gastroenterology</i> , 2010, 138, S-231.	0.6	1
142	44 - Longitudinal Symptom and Quality of Life Outcomes in Patients with Suspected Gastroparesis in Relation to Delays in Gastric Emptying and Generalized Gut Transit: A Prospective, Multicenter Evaluation. <i>Gastroenterology</i> , 2018, 154, S-15.	0.6	1
143	434 â€œ Characterization of Pyloric Tonic and Phasic Pyloric Motor Activity Using Expanded Endoflip Measures Before and After G-Poem for Medication-Refractory Gastroparesis. <i>Gastroenterology</i> , 2019, 156, S-88-S-89.	0.6	1
144	Small Intestinal Motility. , 2020, , 459-471.		1

#	ARTICLE	IF	CITATIONS
145	Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 545-546.	1.9	1
146	Dietary Intake and Nutritional Deficiencies in Patients with Gastroparesis. <i>American Journal of Gastroenterology</i> , 2009, 104, S55.	0.2	1
147	Augmented visceral perception. <i>Current Treatment Options in Gastroenterology</i> , 2001, 4, 339-349.	0.3	0
148	Approach to the Patient with Gas and Bloating. , 0, , 255-270.		0
149	Approach to the Patient with Nausea and Vomiting. , 0, , 205-227.		0
150	Pharmacological Causes and Treatments of Nausea and Vomiting. , 2017, , 119-137.		0
151	Editorial: you bet your life “ medication risk taking by gastroparesis patients in a hypothetical exercise. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1096-1097.	1.9	0
152	3185 A Randomized Controlled Trial Comparing the Nonabsorbable Antibiotic Rifaximin vs. Dietary Intervention Low in Fermentable Sugars (FODMAP) in Irritable Bowel Syndrome. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 31-31.	0.3	0
153	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 999-1000.	2.4	0
154	Response to the letter by Udo Bonnet. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13715.	1.6	0
155	Ancillary testing including barostat, SPECT, and satiety testing. , 2021, , 215-234.		0
156	Title is missing!. , 2020, 15, e0241441.		0
157	Title is missing!. , 2020, 15, e0241441.		0
158	Title is missing!. , 2020, 15, e0241441.		0
159	Title is missing!. , 2020, 15, e0241441.		0
160	Title is missing!. , 2020, 15, e0241441.		0
161	Title is missing!. , 2020, 15, e0241441.		0